Seres Therapeutics
(NASDAQ) MCRB
Seres Therapeutics Financials at a Glance
Market Cap
$89.44M
Revenue (TTM)
$789.00K
Net Income (TTM)
$5.70M
EPS (TTM)
$0.81
P/E Ratio
11.52
Dividend
$0.00
Beta (Volatility)
1.25 (Average)
Dividend
$0.00
Beta (Volatility)
1.25 (Average)
Price
$9.08
Volume
835
Open
$9.22
Price
$9.08
Volume
835
Open
$9.22
Previous Close
$9.08
Daily Range
$8.96 - $9.49
52-Week Range
$6.53 - $29.98
Dividend
$0.00
Beta (Volatility)
1.25 (Average)
Price
$9.08
Volume
835
Open
$9.22
Previous Close
$9.08
Daily Range
$8.96 - $9.49
52-Week Range
$6.53 - $29.98
MCRB News
MCRB: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Seres Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
66
CEO
Thomas J. DesRosier; Ann Marella Thorell, CPA
Website
www.serestherapeutics.comHeadquarters
Cambridge, MA 02139, US
MCRB Financials
Key Financial Metrics (TTM)
Gross Margin
-4%
Operating Margin
-119%
Net Income Margin
7%
Return on Equity
20%
Return on Capital
-79%
Return on Assets
4%
Earnings Yield
8.68%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$89.44M
Shares Outstanding
9.59M
Volume
835
Short Interest
0.00%
Avg. Volume
67.82K
Financials (TTM)
Gross Profit
$3.34M
Operating Income
$93.97M
EBITDA
$89.84M
Operating Cash Flow
$1.12M
Capital Expenditure
$252.00K
Free Cash Flow
$865.00K
Cash & ST Invst.
$45.77M
Total Debt
$82.97M
Seres Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$438.00K
N/A
Gross Profit
$14.24M
N/A
Gross Margin
32.52%
N/A
Market Cap
$89.44M
N/A
Market Cap/Employee
$868.35K
N/A
Employees
103
N/A
Net Income
$15.34M
+1.9%
EBITDA
$17.24M
-18.5%
Quarterly Fundamentals
Net Cash
$37.20M
+38.9%
Accounts Receivable
$360.00K
-92.4%
Inventory
$0.00
N/A
Long Term Debt
$72.58M
-12.5%
Short Term Debt
$10.39M
+19.8%
Return on Assets
4.12%
N/A
Return on Invested Capital
-79.05%
N/A
Free Cash Flow
$14.74M
+62.2%
Operating Cash Flow
$14.71M
+62.2%